上消化道恶性肿瘤患者血清CEA、CA199和SCC联合检测的研究

Value of combined determination of serum CEA,CA19 -9,CA125 in diagnosis of upper gastric tract carcinomas

目的探讨血清肿瘤标记物癌胚抗原(CEA)、唾液酸化岩藻戊糖(CA199)和鳞状上皮细胞癌抗原(SCC)联合检测对上消化道恶性肿瘤的临床诊断价值。方法采用酶联免疫法(ELISA)测定90例上消化道恶性肿瘤患者、90例正常健康者的三种肿瘤标志物(CEA、CA199、SCC)水平。结果肿瘤组三种血清标志物的水平高于对照组(P<0.05);CEA和CA199在腺癌中具有较高的阳性率,SCC在鳞癌中具有较高的阳性率(P<0.05);在不同TNM临床分期患者中,CEA和CA199的阳性率为Ⅳ期>Ⅲ期>Ⅰ～Ⅱ期(P<0.05);SCC的阳性率Ⅰ～Ⅱ期低于Ⅲ期、Ⅳ期(P<0.05),但Ⅲ期和Ⅳ期比较差别无统计学意义(P>0.05)。结论血清肿瘤标志物CEA、CA199和SCC在上消化道恶性肿瘤的诊断、病理类型的鉴别、临床分期的诊断上都有重要的临床价值。

Aim To investigate the clinical value of combined determination of CEA,CA199 and SCC in diagnosing upper gastric tract tumors. Methods Enzyme-linked immunosorbent assay （ELISA） was used to detect CEA,CA199 and SCC in sera of 90 tumor patients and 90 healthy control group. Results The levels of CEA,CA199 and SCC in patient group were significantly higher than that of control group （P〈0.05）; the positive rate of CEA and CA199 in patients with gland cancer patients was relatively higher, the positive rate of SCC in patients with squamous cell carcinoma was higher. The levels of these tumor markers in patients with upper gastric tract malignancies increased as the TNM stages advanced （P〈 0.05）,but level of SCC showed no significant difference between stage III and IV （P〉0.05）. Conclusions CEA,CA199 and SCC, as serum tumor markers, were useful for diagnosis, pathological differentiation and clinical phasing.